Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
- 10 August 2005
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (23) , 5386-5403
- https://doi.org/10.1200/jco.2005.23.648
Abstract
Circulating cytokines, hormones, and growth factors control all aspects of cell proliferation, differentiation, angiogenesis, apoptosis, and senescence. These chemical signals are propagated from the cell surface to intracellular processes via sequential kinase signaling, arranged in modules that exhibit redundancy and cross talk. This signal transduction system comprising growth factors, transmembrane receptor proteins, and cytoplasmic secondary messengers is often exploited to optimize tumor growth and metastasis in malignancies. Thus, it represents an attractive target for cancer therapy. This review will summarize current knowledge of selected intracellular signaling networks and their role in cancer therapy. The focus will be on pathways for which inhibitory agents are currently undergoing clinical testing. Original data for inclusion in this review were identified through a MEDLINE search of the literature. All papers from 1966 through March 2005 were identified by the following search terms: “signal transduction,” “intracellular signaling,” “kinases,” “proliferation,” “growth factors,” and “cancer therapy.” All original research and review papers related to the role of intracellular signaling in oncogenesis and therapeutic interventions relating to abnormal cell signaling were identified. This search was supplemented by a manual search of the Proceedings of the Annual Meetings of the American Association for Cancer Research, American Society of Clinical Oncology, and the American Association for Cancer Research (AARC) –European Organisation for Research and Treatment of Cancer (EORTC) –National Cancer Institute (NCI) Symposium on New Anticancer Drugs.Keywords
This publication has 154 references indexed in Scilit:
- Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProceedings of the National Academy of Sciences, 2005
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of ActionLeukemia & Lymphoma, 2004
- Dual role for mitogen-activated protein kinase (Erk) in insulin-dependent regulation of Fra-1 (fos-related antigen-1) transcription and phosphorylationBiochemical Journal, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- The EORTC Clinical Research Coordinators GroupEuropean Journal Of Cancer, 2002
- Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cellsLeukemia, 2001
- The mitogen activated protein kinase signal transduction pathway: From the cell surface to the nucleusCellular Signalling, 1994
- SH2 and SH3 domainsCurrent Biology, 1993